The U.S. Food and Drug Administration has granted approval for the Abbreviated New Drug Application (ANDA) 078853 for DIVALPROEX SODIUM, manufactured by Bionpharma Inc.
The approved product is an oral, delayed‑release tablet available in three strengths: 125 mg, 250 mg and 500 mg equivalents of valproic acid. All formulations are prescription‑only.
Labeling submissions for this ANDA have been approved on March 18 2014 (submission 6), January 7 2022 (submissions 9, 11, 13) and November 22 2023 (submissions 15, 17).
규제 업데이트2026년 9월 25일•1분 읽기
FDA Approves DIVALPROEX SODIUM (ANDA078853)
FDA grants approval for DIVALPROEX SODIUM tablets (ANDA078853) by Bionpharma Inc., with oral delayed‑release 125 mg, 250 mg and 500 mg equivalents.
PharmaCountry 팀이 정리했습니다 · 출처: FDA.gov
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기